About Javeri
Product & Services
Equity
Derivatives
Mutual Funds
IPO
Corporate Info
Research
Contact Us
Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME
>
CORPORATE INFO
>
COMPANY NEWS
Company
News
Dr. Lal Pathlabs Ltd.
Change Company
BSE Code
539524
ISIN Demat
INE600L01024
Book Value
263.45
NSE Code
LALPATHLAB
Dividend Yield %
0.73
Market Cap
274146.98
P/E
51.98
EPS
62.95
Face Value
10
1 Week
1 Month
3 Months
6 Months
1 Year
20-Aug-2025
Dr. Lal Pathlabs pioneers AI integration in cance...
20-Aug-2025
Dr. Lal PathLabs informs about press release
20-Aug-2025
Dr. Lal Pathlabs surges on pioneering AI integrat...
01-Aug-2025
Dr. Lal PathLabs informs about press release
31-Jul-2025
Dr. Lal PathLabs informs about investor presentat...
31-Jul-2025
Dr. Lal PathLabs informs about press release
31-Jul-2025
Dr. Lal PathLabs informs about record date
24-Jul-2025
Dr. Lal PathLabs informs about analyst meet
25-Jun-2025
Dr. Lal PathLabs expands genomics capabilities wi...
25-Jun-2025
Dr. Lal PathLabs informs about press release
25-Jun-2025
Dr. Lal PathLabs surges on expanding genomics cap...
04-Jun-2025
Dr. Lal PathLabs informs about annual report
04-Jun-2025
Dr. Lal PathLabs informs about BRSR
19-May-2025
Dr. Lal PathLabs informs about analyst meet
08-May-2025
Dr. Lal PathLabs informs about press release
Page
1
of
2
Prev
||
Next
Disclaimer
|
Privacy Policy
| Grievance |
FAQ
|
Sitemap |
Client Registration |
Useful Links
|
Anti Money Laundering
|
Inactive Client Policy
|
Scores
Vernacular Kyc
|
Advisory For Investors
|
Investor Adviser
|
Filing complaints on SCORES - Easy & quick
|
Policy on PMLA
|
Publishing of investor charter information
|
Annexure A – Investor charter of brokers
|
Annexure A – Investor charter of DP
|
Annexure B –Linked content for information to charter for DP
|
Annexure B & C (investor complaint data) broker & DP
|
Investor Charter & Complaints
|
Advisory-KYC Compliance
|
E-Voting NSE
|
E-Voting BSE
|
Details of Client Bank Accounts
|
Risk Disclosure
|
NSE FO Risk disclosure
|
Details of Research Analyst
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by
Accord Fintech Pvt. Ltd.
CLOSE
X
RISK DISCLOSURES ON DERIVATIVES
9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source:
Click Here.